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A B S T R A C T
Oxidative stress has been implicated in a number of human regeneration and disease pro-
cesses including atherosclerosis, pulmonary fibrosis, cancer, and different neurodegenerative
diseases.The aim of this studywas to evaluate the protective effects of Lactobacillus delbrueckii
subsp. lactis DSM 20076 (LL-DSM) and Pediococcus acidilactici NNRL B-5627 (PA-NNRL) against
the hepatic- and nephro-toxicity of fumonisin B1 (FB1) in FB1-treated rats for an experimen-
tal period of 4-weeks. Eighty mature male Sprague-Dawley rats were divided to 12 groups: 1
untreated group; 3 groups fed by a FB1-contaminated diet (50, 100 and 200 mg FB1/kg diet,
respectively); 1 group fed orally by LL-DSM (1 ml/d); 1 group fed orally by PA-NNRL (1 ml/d); 3
groups co-administered by FB1-contaminated diet and LL-DSM (1 ml/d), and 3 groups co-
administered by FB1-contaminated diet and PA-NNRL (1 ml/d). Malonaldehyde (MDA) nitric
oxide, glutathione content, SOD activity, total antioxidant capacity (TAC), total oxidant status
(TOS) and oxidative stress index (OSI) were determined. DPA assay was used to assess apop-
tosis in liver andkidney tissues.Theanimals fedwithFB1-contaminateddiet showedasignificant
increase in oxidative stress markers and DNA fragmentation accompanied with significant
decrease in GSH content, SOD activity, andTAC in liver and kidney tissues, especially at high-
dosage of FB1 (T200). Probiotics antioxidant strains (LL-DSMand PA-NNRL) relatively succeeded
to restore almost all parameters investigated as well as to reduce DNA fragmentation in liver
and kidney tissues. As a conclusion, probiotics may induce its protective role via increasing
the antioxidant capacity, inhibition of lipid peroxidation, scavenging of free radicals and de-
creasing DNA lesions in liver and kidney of experimental animals tested.
© 2016 Production and hosting by Elsevier B.V. on behalf of Shenyang Pharmaceutical
University. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Oxidative stress is classically defined as an imbalance between
pro-oxidants and anti-oxidants in favor of the former, result-
ing in an overall increase in cellular levels of reactive oxygen
species (ROS) [1]. ROS can damage or cause complete degra-
dation (i.e., peroxidation) of essential complex molecules in
the cells, including fat molecules (i.e., lipids), proteins, and
DNA [2]. Although lipid peroxidation evidently may not con-
tribute directly to killing in all instances of oxidative stress,
products of oxidized lipids may themselves initiate further
oxidative damage that could prove fatal. Thus reactive prod-
ucts such as malondialdehyde and 4-hydroxynonenal may
attack amino acid side chains in proteins and cause fragmen-
tation of DNA [3].
Apoptosis is considered to be a common result of oxida-
tive stress caused by ROS production, disturbance of GSH
generation and lipid peroxidation. In addition, activation of
caspase-3 may be one of the events causing an increase in ROS
production, and subsequent lipid peroxidation and reduction
of intracellular GSH levels [4]. Another mechanism of apop-
tosis induction probably involves the inhibition of protein kinase
C, a key hallmark of apoptosis signaling and destructuring of
the endothelial barrier [5]. Endogenous cell metabolism and
different chemicals, drugs,mycotoxins, ionizing radiation, solar
light, cigarette smoking, and air pollution can induce oxida-
tive damage to DNA. It has been considered that oxidative DNA
damage is involved in the development of different diseases,
aging, and cancer [6].
It is well known that some mycotoxins may induce the pro-
duction of free radicals and/or the reduction of antioxidant
defenses [7]. In addition detrimental effects of mycotoxins on
DNA, RNA and protein synthesis together with pro-apoptotic
action further compromise important metabolic pathways, and
consequently, changes in physiological functions including
growth, development and reproduction occur [4]. The impact
of the mycotoxins on the immune system of exposed animals
is a matter of concern because, by this way, these natural-
occurring toxins may predispose farm animals to the infectious
diseases, which could result in economic losses for the live-
stock industry [8].
Carcinogenic and neurotoxic fumonisins, another class of
fungal mycotoxins produced by Fusarium species and other
fungal species that ubiquitous in Nature, contaminate food,
mainly corn (Zea mays L) and other grains throughout theWorld,
represent a significant hazard to the food chain [9]. Major
fumonisin fungi species–mycotoxin associations are derived
from F. verticilliodes (formerly known as F. moniliforme) and
F. proliferatum. Minor Fumonisin sources include F. nygamai,
F. napiforme, F. thapsinum, F. anthophilum and F. dlamini [10].
Fumonisin induced porcine pulmonary edema (PPE) is a well-
established toxin specific adverse effect [11], and fumonisin also
has the potential to negatively impact the food and feedmarket
due to contaminated grain [12]. One of the initial events that
occur in the target organs exposed to fumonisin is apoptosis,
which might be a consequence of the inhibition of ceramide
synthetase and alterations in sphingolipid metabolism.
Fumonisin B (FB) evokes oxidative stress, which may contrib-
ute at least in part to FB toxicity and carcinogenicity [13]. El-
Nekeety et al. [14] demonstrated that FB administration
enhanced lipid peroxidation as indicated by the significant in-
crease in MDA level, which directly results to free radical-
mediated toxicity.
Fumonisin B1 (FB1), the most common and highest toxic
of fumonisins species, is the focus of governments and sci-
entists throughout the world due to the strong toxicity and
potent carcinogenicity shown in animal studies [15]. FB1 is a
nephrotoxin in all species tested, a carcinogen in rodents and
a reproductive toxicant in rodents and likely in humans [16].
It can induce apoptosis in vitro in different cultured cell lines
and in vivo in liver and kidney of rodents, where production
of proinflammatory cytokines such as TNFα and IFNγ is an im-
portant mediator of apoptosis [17]. The Food and Drug
Administration (FDA) has issued maximum residue limits in
maize, maize byproducts in food and animal feeds, which are
2000–4000 and 5000–100,000 μg/kg total fumonisins
(FB1 + FB2 + FB3) for human foods and animal feeds, respec-
tively [18,19].
Probiotics have been proven to exert health promoting in-
fluences in human and animals [20,21]. Probiotics are effective
compounds in the treatment and protection of some alimen-
tary track infections as they alter the intestinal flora in favor
of beneficiary microorganisms.They are used to increase feed
conversion as well as to decrease malnutrition and stress con-
ditions [22]. Most Lactobacillales are rather tolerant to H2O2.
For example Lactobacillus lactis IL1403, generates H2O2 by NADH
dehydrogenation but does not possess catalase for H2O2 removal
[23–25]. Some of the beneficial properties of probiotics are
related to their capacity to adhere to or bind different targets.
L. rhamnosus GG strain (ATCC 53103) and L. rhamnosus LC-705
strain (DSM 7061) can bind toxic compounds, such as afla-
toxin B1 [26], mutagens from food [27], or microcystin-LR [28].
Recently, many in vitro and in vivo investigations indicated that
probiotics can play an important role in the body’s natural
processes of detoxification and elimination of FB1 [29–31]. The
present study describes the ameliorating influences of Lacto-
bacillus delbrueckii subsp. lactis DSM 20076 and Pediococcus
acidilactici NNRL B-5627 on FB1-induced hepatotoxicity and
nephrotoxicity in male rats fed with incremented doses of
FB1-contaminated diets along an experimental period of
4-weeks.
2. Materials and methods
2.1. Chemicals
Ortho-dianisidine dihydrochloride, sodium tungestate, Tris-
HCl, diphenylamine (DPA), and H2O2 were purchased from Sigma
Chemical Company (St. Louis, Mo, USA). 5,5 dithiobis- 25-
nitrobenzoic acid (DNTB) and NADH were bought from MP
Biomedicals, LLC, France. Napthylethyline diamine hydrochlo-
ride (NEDD) was purchased from Park Scientific Limited,
Northampton, UK. Phenazine methosulphate (PMS) was pur-
chased from Lobachemie, USA. Nitro blue tetrazolium (NBT)
was purchased fromAlliance Bio, USA.Thiobarbituric acid (TBA)
was purchased from Acros, New Jersey, USA. Xylenol orange
and sodium pyrophosphate were purchased from Alpha
Chemika, Mumbai, India. Trichloroacetic acid was purchased
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from SD Fine-Chem Limited, Mumbai, India. Fumonisin B1 was
purchased from Cayman Chemicals Company, USA, dis-
solved in acetonitrile-water in the ratio 1:1 (v/v) and kept at
−20oC until used.All other chemicals and reagents were of ana-
lytical grade and highest quality available commercially. Corn
samples were purchased from Egyptian local market.
2.2. Preparation of Fusarium-contaminated corn and
probiotic cultures
Culturematerial of Fusariummoniliforme (EMF1) as FB1-producing
isolate was prepared as previously described [32] and used in
the experiment in order to study the protective influence of
Lactobacillus delbrueckii subsp. lactis DSM 20076 and Pediococcus
acidilactici NNRL B-5627 against fumonsin B1 produced in corn
culture contaminated by F. moniliforme (EMF1) strain.This strain
was previously isolated and assessed for its ability to produce
FB1 toxin (GB accession number: KJ546424) [30].
Pediococcus acidilactici NNRL B-5627 (PA-NNRL) strain was ob-
tained from the Northern Regional Research Laboratory (NRRL,
Peoria, IL, USA) and Lactobacillus delbrueckii subsp. lactis DSM
20076 (LL-DSM) strain was obtained from German Collection
of Microorganisms and Cell Cultures (DSM), Braunschweig,
Germany. Stock cultures of probiotics were maintained at −80°C
on MRS medium with 25% (v/v) glycerol. To produce fresh cul-
tures, the probiotic strains were propagated at 30°C for 14–
16 h, then at 37°C for 14–16 h, before experimental use.
Whenever needed, probiotics cultures were given orally by
gavages at a daily dose of 1010 CFU/ml for 4-weeks.
2.3. Animals and experimental design
All animal experiments were performed according to the Guide
for the Care and Use of Laboratory Animals, National Insti-
tutes of Health (Institute of Laboratory Animal Resources, 1996).
Male Sprague-Dawley rats (weight 100–120 g) were obtained
from the animal house of the Faculty of Veterinary, Cairo Uni-
versity, Egypt. The rats were maintained at approximately 23–
25 °C with a 12 h light/dark cycle and received basal diet and
tap water ad-libitum for one week acclimation period. Eighty
rats were housed in metal cages in which they chosen
randomly then were divided into 12 experimental groups (6
or 7 rats each). The experimental design was conducted as
shown in Table 1.
After 4-weeks, rats were anesthetized by sodium pentobar-
bital (4%, 40 mg/kg), then kidney as well as liver were quickly
removed and placed in chilled phosphate buffer, pH 7.4. The
tissues were freed from adhering blood by repeated washing
with the same buffer and then divided into two portions: one
kept as a stock and the other used for preparation of tissue
homogenates.
2.4. Preparation of liver and kidney homogenates
Liver and kidney homogenate were prepared using the method
determined by Guidet and Shah [33]. One gram of tissue was
washed in ice cold isotonic saline containing 1 mM EDTA.The
tissues were then homogenized separately in 8 ml of cold buffer
(50 mM potassium phosphate buffer, pH 7.4, containing 1 mM
EDTA and 1 mM 2-mercaptoethanol) using a Potter-Elvejham
homogenizer at 4 °C. The crude tissue homogenate was then
centrifuged at 8000 × g for 15 min at 4 °C and the superna-
tant was removed and kept at −80 °C for estimation of
malondialdehyde (MDA), reduced glutathione (GSH), superox-
ide dismutase (SOD) and nitric oxide (NO), total oxidative statues
(TOS), total antioxidant capacity (TAC) and oxidative stress index
(OSI). The protein concentration of the clarified homogenate
was estimated according to the method of Lowry et al. [34].
2.5. Markers of oxidative stress and antioxidant capacity
2.5.1. Determination of lipid peroxidation in terms of
malonaldehyde (MDA)
The lipid peroxidation was measured byTBARS formation [35].
The reaction mixture contained 0.1 ml tissue homogenate,
0.2 ml 8.1% sodium dodecyl sulphate (SDS), 1.5 ml 20% acetic
acid (pH 3.5 adjusted with 1 Ν NaOH) and 1.5 ml 0.8% aqueous
solution of thiobarbituric acid (TBA). The mixture was finally
made up to 4.0 ml with distilled water, then heated at 95 °C
for 30 min on a water bath.After cooling under tap water, 1.0 ml
of distilled water and 5.0 ml of a mixture of n-butanol and pyri-
dine (15:1 v/v) were added and then the mixture was shaken
Table 1 – The experimental design of rat treatments along 4-weeks exposure to Fumonisin B1 and/or probiotic lactic acid
bacteria.
Form of diets Rat groups Treatments Code
Normal diet Group 1 Control NC
FB1-contaminated diets Group 2 50 mg FB1/kg diet T50
Group 3 100 mg FB1/kg diet T100
Group 4 200 mg FB1/kg diet T200
Probiotic-supplemented diets Group 5 Lactobacillus delbrueckii subsp. lactis DSM 20076 (1010 CFU/ml) LL-DSM
Group 6 Pediococcus acidilactici NNRL B-5627 (1010 CFU/ml) PA-NNRL
FB1 plus probiotic diets Group 7 (50 mg FB1/kg diet) + LL (1010 CFU/ml) T50-LL
Group 8 (50 mg FB1/kg diet) + PA (1010 CFU/ml) T50-PA
Group 9 (100 mg FB1/kg diet) + LL (1010 CFU/ml) T100-LL
Group 10 (100 mg FB1/kg diet) + PA (1010 CFU/ml) T100-PA
Group 11 (200 mg FB1/kg diet) + LL (1010CFU/ml) T200-LL
Group 12 (200 mg FB1/kg diet) + PA (1010CFU/ml) T200-PA
Note: Each group consists of six or seven rats.
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vigorously on a vortex mixer. After centrifugation at 2200 × g
for 5 min the absorbance of the organic layer was measured
immediately at 535 nm. MDA concentration was calculated:
MDA conc. A B x wt. of tissue used
nmol g wet ti
= −( ) × ×( )[ ]
=
1 5 0 156 0 5. . .
ssue.
(1)
where: A, the absorbance of sample; B, the absorbance of blank;
1.5, the total volume used for measurement; 0.156, the absor-
bance for 1 nM solution of MDA measured in 1 cm thick cell
at 535 nm; 0.5, the used volume of tissue (liver or kidney)
homogenate.
2.5.2. Determination of superoxide dismutase (SOD) activity
Measurement superoxide radical scavenging activity was carried
out following a standardmethod [36].The reactionmixture con-
tained 1 ml of nitro blue tetrazolium (NBT) solution (312 μM
prepared in phosphate buffer, pH 7.4), 1 ml NADH solution
(936 μM prepared in phosphate buffer, pH 7.4). Standardized
50 times methanol diluted different extracts of the samples
were then added. Finally, reaction was accelerated by adding
100 μl phenazine methosulphate (PMS) solution (120 μM pre-
pared in phosphate buffer, pH 7.4) to the mixture.The reaction
mixture was incubated at 25 °C for 5 min and absorbance at
560 nm was measured against methanol as control. Percent-
age of inhibition was calculated:
% complete inhibition
Abs. of control Abs. of sample Abs. of cont= −( ) rol × 100. (2)
2.5.3. Determination of reduced glutathione (GSH) content
Reduced glutathione (GSH) was assayed by the method of Prins
and Loose [37]. The method utilized metaphosphoric acid for
protein precipitation and 5,5-dithiobis (2-nitrobenzoic acid)
(DTNB) for color development. The absorbance was mea-
sured at 412 nm.
2.5.4. Nitric oxide (NO) scavenging activity
Nitric oxide generated from sodium nitroprusside in aqueous
solution at physiological pH interacts with oxygen to produce
nitrite ions, which were measured by Griess reaction [38,39].
The reaction mixture (3 ml) containing sodium nitroprusside
(10 mM) in phosphate buffer saline and the tested extracts (10,
25, 50 or 100 μg/ml) was incubated at 25 °C for 150 min. After
incubation, 1.5 ml of the reaction mixture was removed and
1.5 ml of the Griss reagent (1% sulphanilamide, 2% orthophos-
phoric acid and 0.1% napthylethyline diamine hydrochloride)
was added. The absorbance of the chromophore formed was
read at 546 nm.A decrease in absorbance indicated a high scav-
enging activity [40].
2.5.5. Measurement of total antioxidant capacity (TAC)
Total antioxidant capacity (TAC) of liver and kidney
homogenates was determined using an automated measure-
ment method as previously described [41]. In brief, 200 μl of
Reagent 1 [(o-dianisidine (10 mM), ferrous ion (45 mM) in the
Clark and Lubs solution (75 mM, pH 1.8)] was mixed with 10μl
Reagent 2 [H2O2 (7.5 mM) in the Clark and Lubs solution].Then
5 μl of the sample was added. Where, Clark and Lubs solu-
tion (75 mM, pH 1.8) was prepared by dissolving 5.591 g of KCl
in 1000 ml of deionized water (final concentration, 75 mM) and
diluting 6.41 ml hydrochloric acid (36.5%) to 1000 ml with de-
ionized water (final concentration, 75 mM). The prepared KCl
solution (800 ml) was mixed with 200 ml of HCl solution under
pH meter (final pH 1.8). The absorbance was measured at
412 nm. The results are expressed as mMTrolox equivalent/l.
The assay has excellent precision with coefficients of varia-
tion less than 3%.
2.5.6. Measurement of total oxidant status (TOS)
Total oxidant status (TOS) of liver and kidney homogenates was
determined using an automated measurement method as pre-
viously described [42]. In brief, 225 μl solution of reagent 1
(xylenol orange 150 μM, NaCl 140 mM and glycerol 1.35 M in
25 mM H2SO4 solution, pH 1.75) was mixed with 11 μl reagent
2 (ferrous ion 5 mM and o-dianisidine 10 mM in 25 mM H2SO4
solution). Then 35 μl of the sample was added. The absor-
bance wasmeasured at 560 nm.The color intensity, which could
be measured spectrophotometrically, was related to the total
amount of oxidant molecules present in the sample.The assay
was calibrated with hydrogen peroxide and the results were
expressed in terms of μM H2O2 equivalent/l.
2.5.7. Determination of oxidative stress index (OSI)
The ratio of TOS to TAC was accepted as the oxidative stress
index (OSI). For calculation, the resulting unit of TAC was
changed to mM, and the OSI value (Arbitrary Unit) was calcu-
lated according to a formula stated by Horoz et al. [43]:
OSI TOS MH O equivalent l TAC mM Trolox equivalent l= ( ) ( )μ 2 2 .(3)
2.6. Apoptosis assay: quantification of fragmented DNA
using diphenylamine (DPA)
DPA assay was conducted following the method of Gibb et al.
[44]. DPA solution was prepared by dissolving 150 mg DPA in
10 ml glacial acetic acid, 150 ml of sulfuric acid and 50 ml ac-
etaldehyde (16 mg/ml). The tissues of livers and kidneys were
prepared in 0.5 ml of lyses buffer containing 10 mM tris-HCl
(pH 8), 1 mM EDTA, 0.2% triton X-100, centrifuged at 10,000 × g
for 20 min at 4 °C. The pellets were re-suspended in 0.5 ml of
lyses buffer. Half ml of 25% trichloroacetic acid (TCA) was added
to the pellets (P) and the supernatants (S) then incubated at
4 °C for 24 h. The samples were centrifuged for 20 min at
10,000 × g at 4 °C and the pellets were suspended in 80 ml of
5% TCA, followed by incubation at 83 °C for 20 min. Subse-
quently, 160 ml DPA solution was added to each sample and
incubated at room temperature for 24 h.The proportion of frag-
mented DNAwas calculated from absorbance reading at 600 nm
using the formula:
% .Fragmented DNA OD S OD S OD P= ( ) ( ) + ( )[ ] × 100 (4)
2.7. Statistical analysis
Data from these studies were obtained from a minimum of six
independent experiments (n = 6, for each treatment), and as-
sessed by a one-way ANOVA followed by either Tukey Kramer
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multiple comparisons test or Bonferroni’s post hoc test using
SPSS computer program software, version 20.All data were ana-
lyzed through a completely randomized design (CRD).
Differences were considered significant at the P ≤ 0.05 level.
3. Results
3.1. Markers of oxidative stress and antioxidant capacity
The oxidative stress played a role in FB1 hepatotoxicity and
nephrotoxicity. The data show that FB1 treatment signifi-
cantly increased the production of MDA, NO and TOS starting
from the concentration of 50 mg/kg diet accompanied with a
significant decrease in SOD, GSH, and TAC. FB1-induced lipid
peroxidation was measured as an increase in the concentra-
tion of MDA in both liver and kidney tissues (Table 2). In FB1-
treated rats, the level of MDA in liver and kidney tissues were
significantly increased compared to untreated and probiotics
supplemented groups at P < 0.05. Increased MDA concentra-
tions were observed in T50, T100, T200 groups already after a
4-weeks treatment with FB1 by 1.97, 3.81 and 4.67, respec-
tively in liver tissues and by 1.90, 2.95 and 4.09, respectively
in kidney tissues. On the other hand, rats received either LL-
DSM or PA-NNRL, showed a notable reduction in MDA levels
when compared to control P > 0.05. Furthermore, co-
administration of LL-DSM or PA-NNRL along with FB1 resulted
in a significant reduction in MDA levels in both liver and kidney
tissues compared to FB1-treated groups at P < 0.05. In this
groups, the levels of MDA in liver and kidney tissues were sig-
nificantly higher than that of control group (P < 0.05), exception
in T50-LL and T50-PA which were normalized to control level.
Regarding GSH content, rats given either LL-DSM or PA-
NNRL exhibited an increase in GSH content as compared to
control, which was significant at P < 0.05 in case of liver and
kidney tissues (Table 2). GSH was markedly low in liver tissues
of rats groups T50, T100 and T200, by 3.33, 26.7 and 65.6% re-
spectively, and by 0.96, 32 and 68% in kidney tissues in
comparison with control; this reduction was statistically sig-
nificant at P < 0.05. A significant increase in GSH level was
shown in rats received FB1 and co-administrated with LL-
DSM or PA-NNRL when compared with FB1 groups at P < 0.05.
This enhancement was significantly higher than that of control
with an exception in T200-LL and T200-PA groups, which were
just normalized to control level.
As shown in Table 3, FB1 toxicity (T50, T100 and T200) sig-
nificantly decreased activities of SOD enzyme in liver and kidney
tissues, as compared to control group at P < 0.05. However, the
activity of SOD in FB1 groups’ co-administrated with LL-DSM
or PA-NNRL was significantly increased as compared to the FB1
groups. This increase in the protective groups T50-LL, T50-PA,
T100-LL and T100-PA was still significantly higher or equal to
that of control at P < 0.05. In addition, we observed a higher
elevation in SOD activity of the liver tissues response to
probiotics in protective groups (T200-LL: 0.29 + 0.070; T200-
PA: 0.35 + 0.037) in relation to infected groupT200 (0.14 + 0.049).
Besides, high elevation in SOD activity of the kidney tissues
response to probiotics in protective groups (T200-LL: 0.25 + 0.09;
T200-PA: 0.33 + 0.02) in comparison to infected group T200
(0.17 + 0.01) was also observed. Meanwhile, liver and kidney
tissues of rat groups LL-DSM and PA-NNRL showed a signifi-
cant enhancement in SOD activity at P < 0.05 compared to those
of the control group.
A positive correlation was observed between increasing con-
centrations of FB1 groups and nitric oxide levels in both liver
and kidney tissues. As shown in Table 2, liver tissues of FB1-
treated groups (T50,T100 andT200) have recorded a significant
elevation of NO levels, by 25%, 69.2% and 151.2% respectively;
however, NO recorded lesser values in kidney tissues by 19.5%,
63.4% and 134% respectively. The administration of either LL-
DSM or PA-NNRL along with FB1 succeeded to decrease NO
levels in both liver and kidney tissues but still their levels were
higher than that of the untreated group. Furthermore, no dif-
ferences were detected in NO levels in LL-DSM and PA-NNRL
groups compared to control group.
TAC, TOS levels and OSI in FB1-treated groups, protective
groups and controls are shown in Table 4. TOS and OSI were
significantly higher in FB1-treated rats than control at P < 0.05,
while TAC was significantly lower (P < 0.05). A significant and
positive correlation was observed between TAC and adminis-
Table 2 – Values of MDA and GSH levels in liver and kidney of rats treated with FB1 and/or probiotic LAB.
Groups Liver Kidney
MDA
(nM/mg protein)
GSH
(nM/mg protein)
MDA
(nM/mg protein)
GSH
(nM/mg protein)
NC 1.51 + 0.214a 30.91 + 1.03d 1.42 + 0.68a 35.38 + 1.574c
T50 1.97 + 0.155b 29.88 + 1.03c,d 1.90 + 0.02b 35.04 + 1.030c
T100 3.81 + 0.928c 22.67 + 2.72b 2.95 + 0.53c 24.04 + 1.574b
T200 4.67 + 0.721d 10.64 + 0.59a 4.09 + 0.17d 11.33 + 1.030a
LL-DSM 1.05 + 0.599e 49.47 + 2.06f 1.12 + 0.56e 55.31 + 4.290f
PA-NNRL 1.28 + 0.356e 54.28 + 2.59g 1.15 + 0.55e 57.71 + 1.030f
T50-LL 1.57 + 0.256a 47.06 + 2.14f 1.45 + 0.44a 45.69 + 1.574e
T50-PA 1.55 + 0.077a 50.15 + 0.59f 1.84 + 0.11a 48.44 + 3.091e
T100-LL 1.90 + 0.096b 36.75 + 1.19e 1.79 + 0.11b 40.19 + 1.785d
T100-PA 1.94 + 0.172b 37.44 + 4.16e 1.94 + 0.14b 42.25 + 1.785d
T200-LL 2.602 + 0.0693c 28.79 + 1.78c 2.121 + 0.21c 32.29 + 1.574c
T200-PA 2.711 + 0.258c 30.23 + 1.19c,d 2.89 + 0.22c 33.66 + 0.595c
Note: Values are expressed as means ± SD of six replicates. Statistical analysis is carried out using one way analysis of variance (ANOVA) by
SPSS program, V 20. Means with the same superscript letters within the same column are not significantly different (P ≤ 0.05).
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tration of either LL-DSM or PA-NNRL (P < 0.05). On the contrary,
TOS level and OSI were negatively correlated with probiotic
treatments (P < 0.05). In addition, liver tissues of T100 andT200
groups have recorded significant elevations inTOS by 60.82 and
130.72%, respectively. However, in kidney tissues the eleva-
tion reached 90.13 and 145.50%, respectively, compared to those
of control group. Such oxidative modification is an index of oxi-
dative stress and these abnormalities were prevented by
supplementation of probiotics. It was, also found that rats ad-
ministrated either LL-NNRL or PA-DSM along with FB1 doses
showed an increase in the antioxidant capacity. Moreover, this
capacity decreased when the oxidative stress increased, as re-
vealed by the higher OSI values in rats treated with FB1. The
overall data indicated that LL-NNRL and PA-DSM have a broad
range of bio-modulatory properties, which alleviated the FB1-
oxidative stress and improved their antioxidant capacity.
3.2. DPA assay (DNA fragmentation)
FB1-induced apoptosis in liver and kidney tissues was evalu-
ated by determination of genomic DNA fragmentation using
the DPA assay. As shown in Figs 1 and 2, treatment with FB1
triggered a marked increase in the percentage of DNA frag-
mentation in liver and kidney tissues compared to that in the
untreated rats. It was found that FB1 induced a dose-dependent
genomic DNA fragmentation. The percentage of DNA frag-
mentation wasmore pronounced in rats treated with the higher
dose of FB1 (200 mg/kg diet) compared to the other treated
groups: T50 and T100. The percentage of genomic DNA frag-
mentation in FB1-treated groups (T50,T100 andT200) recorded
18, 22.5 and 37.40%, respectively, in liver tissues (Fig. 1), while
in the kidney tissues (Fig. 2), recorded 15.25, 20.5 and 28.8%,
respectively. Moreover, the data revealed that liver was more
sensitive to FB1 toxicity than kidney. DNA fragmentation in LL-
DSM and PA-NNRL groups was comparable to that of the control
group in both liver and kidney tissues. However, those treated
with FB1 and co-administrated with LL-DSM or PA-NNRL
showed a decrease in the percentage of DNA fragmentation
in liver and kidney tissues compared to FB1-treated groups.
This reduction was comparable to that of control group, except
of T200-LL and T200-PA groups, where it remains signifi-
cantly high at P ≤ 0.05. Furthermore, treatment with LL-DSM
or PA-NNRL significantly brought down the percentage of the
DNA damage in liver tissues of theT200-LL andT200-PA groups
to 25.05 and 23.4% respectively, while the levels of reduction
in the kidney tissues were 22.3 and 21.5 %, respectively. As
overall, rat groups treated with FB1 and co-administrated orally
by PA-NNRL presented much reduction in DNA fragmenta-
tion compared to LL-DSM.
4. Discussion
Authorization of probiotics for use in pharmaceutical prod-
ucts and food supplements, as there is an increase demand
for natural products as alternative medicines, focuses the at-
tention to verify the ability of these bacteria to reduce pathogens
and toxins adhesion to surfaces. Thus, our study focused on
the protective role of P. acidilacticiNNRL B-5627 and Lb. delbrueckii
subsp. lactis DSM 20076 against the oxidative stress and apop-
tosis of FB1 toxicity in male rats. Fumonisins is well known
to disrupt sphingolipid metabolism, altering the cell mem-
brane and causing cytotoxicity [45], while FB1 is reported to
induce lipid peroxidation, which may affect DNA integrity,
leading to DNA oxidized bases [46,47].
In this study, treatment of male rats with FB1 resulted in
a significant increase in lipid peroxidation marker (MDA) and
decrease in GSH content and SOD activity in both liver and
kidney tissues. Similarly, several reports indicated that FB1 in-
creased lipid peroxidation [48,49] and the production of reactive
oxygen species (ROS) in animal models or exposed cells [14,50].
Recently, Hassan et al. [51] showed that the levels of lipid
peroxidation as an oxidative stress marker induced in liver and
kidney were significantly increased while the levels of anti-
oxidant GSH were significantly decreased in FB1-treated groups
compared to their levels in the normal controls.
FBs inducing hepatotoxicity by their oxidative damage effects
have been observed in few studies in vitro and in vivo at high
doses, such as in rats fed high dose of 250 mg FB1/kg diet for
Table 3 – Values of SOD and NO activity in liver and kidney of rats treated with FB1 and/or probiotic LAB.
Groups Liver Kidney
SOD
(U/g protein)
NO
(μM/g protein)
SOD
(U/g protein)
NO
(μM/g protein)
NC 0.37 + 0.044d 0.39 + 0.004b 0.36 + 0.02d,e 0.41 + 0.0047b
T50 0.34 + 0.030c,d 0.49 + 0.002b 0.35 + 0.014c,d,e 0.49 + 0.0050b
T100 0.27 + 0.020b 0.66 + 0.001a 0.28 + 0.04b,c 0.67 + 0.0022a
T200 0.14 + 0.049a 0.98 + 0.004a 0.17 + 0.01a 0.96 + 0.0004a
LL-DSM 0.53 + 0.032f 0.40 + 0.036b 0.50 + 0.03g,h 0.45 + 0.1205b
PA-NNRL 0.59 + 0.020f 0.43 + 0.054b 0.54 + 0.06h 0.43 + 0.0026b
T50-LL 0.45 + 0.008e 0.42 + 0.046e 0.43 + 0.02f,g 0.44 + 0.0462d
T50-PA 0.46 + 0.014e 0.46 + 0.023d 0.43 + 0.02f,g 0.47 + 0.0272d
T100-LL 0.37 + 0.054d 0.48 + 0.008c 0.42 + 0.03e,f 0.49 + 0.0060c
T100-PA 0.41 + 0.041d,e 0.51 + 0.0153c 0.44 + 0.1f,g 0.51 + 0.0318c
T200-LL 0.29 + 0.070b,c 0.55 + 0.004b 0.25 + 0.09b 0.59 + 0.0098b
T200-PA 0.35 + 0.037c,d 0.52 + 0.016b 0.33 + 0.02c,d 0.52 + 0.0203b
Note: Values are expressed as means ± SD of six replicates. Statistical analysis is carried out using one way analysis of variance (ANOVA) by
SPSS program, V 20. Means with the same superscript letters within the same column are not significantly different (P ≤ 0.05).
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21 d [52], rats fed 0.08–0.16 mg FB1/100g b.w/d for 2 years [53],
rats injected IP with 0.5 mg FB1/kg b.w/d for 7 d [54], and also
in cell culture [55]. In contrary to our results, FBs failure at low
dose to increase oxidative damages parameters was reported
in ducks, which received 45 mg FB1/kg b.w. by daily oral ad-
ministration over 12 d [56], and other animal species, such as
rats, which consumed contaminated diet at level of 10 mg FB1/
kg diet for 21 d [52]. Although our results were in concordance
with the studies mentioned above with respect to the in-
crease in oxidative stress, this would be the first study on
oxidation capacity of FB1 subjects as determined using mea-
surement of TOS along with measurement of TAC level and
calculation of OSI.
On the other hand, nitric oxide (NO) was defined as an im-
portant chemical mediator generated by endothelial cells,
macrophages, neurons, etc. and was involved in the regula-
tion of various physiological processes. Excess concentration
of NO is associated with several diseases. Oxygen reacts with
the excess NO to generate nitrite and peroxynitrite anions,
which act as free radicals [57]. In our study, levels of NO in liver
and kidney tissues were significantly increased in FB1-treated
rats compared to both untreated and probiotic supplemented
groups at P < 0.05. In another study, it was demonstrated that
pretreatment with FB significantly enhanced NO release by both
resident untreated and IFN-g-activated macrophages, suggest-
ing the potential involvement of FB in promoting an
inflammatory response [58].
Numerous in vitro, in vivo, human, and epidemiological
studies have provided evidence of the chemopreventive effects
of LAB.These effects act via diverse mechanisms, including al-
teration of the gastrointestinal microflora, enhancement of the
host’s immune response, and antioxidative and antiproliferative
activities [59]. Kaizu et al. [60] found that Lactobacillus sp. SBT
2028 exerted the strongest antioxidant effects out of 570 strains
of LAB. Lin and Yen [61] demonstrated that 19 strains of LAB
exhibited antioxidant activities of 7–12% in intracellular cell-
free extracts, which was due to their metal-ion-chelating and
ROS-scavenging abilities. Lactobacillus acidophilus and
Bifidobacterium longum inhibit lipid peroxidation, as demon-
strated by two methods in which linoleic acid and the cell
membrane of osteoblasts were used for lipid peroxidation. Both
intact-cell and intracellular-cell-free extracts exerted antioxi-
dant activities [62]. Heat-killed cells of Lactobacillus acidophilus
606 also exert antiproliferative activity [63], which is due to the
soluble polysaccharide fraction; this fraction also exhibits potent
antioxidant activity. Although, this study observed that in
Lactococcus lactis even in a wild-type strain and mutant KatE
could contribute to limiting the DNA degradation [64]. In view
of the beneficial effects of probiotics mentioned above, we de-
signed the experimental procedure.
In response to probiotics treatment, our results showed that
the administration of LL-DSM or PA-NNRL to FB1-intoxicated
rats ameliorated the induced oxidative stress comparable to
control, where MDA, NO, TOS and OSI decreased, along with
increased SOD activity GSH and TAC contents. Zoghi et al. [65]
reported that probiotic LAB have a significant potential for in-
activation of toxins by surface binding due to great adhesive
properties of S-layer proteins in their cell wall. Deabes et al.
[66] also reported that mice received Lactobacillus rhamnosus
strain GG (ATCC 53013) before aflatoxins gavage, and showed
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a significant amelioration in oxidative status in both liver
and kidney, by increasing the contents of GSH and SOD
activity.
Apoptosis is a specialized process of cell death that is part
of the normal development of organs and tissue mainte-
nance, and may also occur as a response to various
environmental stimuli, indicating toxicity. Since apoptosis can
play a critical role in the development of cancer, the ability of
toxins to induce apoptosis appears to be related to their toxi-
cological effects [67]. Regarding genotoxicity our results clearly
showed that FB1 has cytotoxic effect to liver and kidney tissues
along a genotoxic effect, causing a DNA fragmentation in both
tissues. A previous study in our lab also reported that admin-
istration of FB1 resulted in excessive malfunctions in liver and
kidney with concomitant increase in DNA damage of rat blood
plasma tested [31]. Omar [68] described in vivo FB1 increases
oxidative damage of the DNA, as measured by increased breaks
of its strands and MDA adducts in rat liver and kidney. Another
action mechanism of FB1 involves the disruption of the de novo
sphingolipid biosynthesis pathway by inhibition of the enzyme
ceramide synthase. The inhibition of sphingolipid biosynthe-
sis disrupts numerous cell functions and signaling pathways,
including apoptosis and mitosis, thus potentially contribut-
ing to carcinogenesis through an altered balance of cell death
Fig. 1 – The effect of probiotic lactic acid bacteria on FB1-induced DNA damage in rat liver exposed in vivo. The level of DNA
strand breaks is expressed as the percentage of DNA in the supernatant. Values are expressed as means ± SD of six
replicates. Statistical analysis is carried out using one way analysis of variance (ANOVA) by SPSS program, V 20. Means
with the same superscript letters are not significantly different (P ≤ 0.05).
Fig. 2 – The effect of probiotic lactic acid bacteria on FB1-induced DNA damage in rat kidney exposed in vivo. The level of
DNA strand breaks is expressed as the percentage of DNA in the supernatant. Values are expressed as means ± SD of six
replicates. Statistical analysis is carried out using one way analysis of variance (ANOVA) by SPSS program, V 20. Means
with the same superscript letters are not significantly different (P ≤ 0.05).
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and replication [68]. Furthermore, Domijan [69] suggested that
FB1 has different effects on cell death/cell growth from pro-
apoptotic and growth inhibitory to anti-apoptotic and growth-
stimulatory. A previous study hypothesized that the TNF/Fas
pathway involved with FB1-induced apoptosis and the induc-
tion of TNF-like pathway in FB1-treated cells has relevance to
its toxic and carcinogenic properties [70]. FB1 also causes DNA
damage and induces caspase-3 activity, suggesting a role in a
cascade of events leading to apoptosis, in rat astrocytes [50].
In agreement with the previous studies, our findings indicate
the in vivo FB1-induced apoptotic DNA fragmentation in liver
and kidney tissues, which was restored by probiotics
supplementation.
5. Conclusion
Our results confirmed that the liver and kidney as the target
organs in FB1-induced rat toxicosis and indicated that expo-
sure to FB1 would generate free radicals, which resulted in the
elevation of hepatic and renal lipid peroxidation along with a
reduction in the antioxidant enzymes such as SOD and GSH
content. In addition, FB1 caused severe apoptotic effects assets
by increasing the genomic DNA fragmentation in both liver and
kidney tissues. In addition, the current results indicate that oral
administration of LL-DSM or PA-NNRL cultures to rats signifi-
cantly attenuates FB1-induced toxicity by means of preventing
oxidative stress, recovering nitric oxide content to the control
level, and maintaining GSH content, as well as a stable activ-
ity of SOD, and a protection against FB1-induced DNA
fragmentation. A probiotic antioxidant strain itself was safe at
the tested doses and it may be a candidate for the preven-
tion as well as treatment of liver and kidney diseases. It restores
the different parameters tested. The protective effects of P.
acidilacticiNNRL B-5627 and Lb. delbrueckii subsp. lactisDSM 20076,
which may be due to the ability to eliminate ROS in the di-
gestive tract of animals and humans, could have applications
for treatment of inflammatory diseases or post-cancer drug
treatments. Consequently, probiotic lactic acid bacteria are rela-
tively useful and reasonable for treatment of FB1 toxicity.Thus,
further studies would be necessary to assess the protective role
of these probiotic bacteria after FB1 intoxication of rats.
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